These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

587 related items for PubMed ID: 28454118

  • 1. Simultaneous exposure to FcγR and FcαR on monocytes and macrophages enhances antitumor activity in vivo.
    Li B, Xu L, Tao F, Xie K, Wu Z, Li Y, Li J, Chen K, Pi C, Mendelsohn A, Larrick JW, Gu H, Fang J.
    Oncotarget; 2017 Jun 13; 8(24):39356-39366. PubMed ID: 28454118
    [Abstract] [Full Text] [Related]

  • 2. Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding.
    Borrok MJ, Luheshi NM, Beyaz N, Davies GC, Legg JW, Wu H, Dall'Acqua WF, Tsui P.
    MAbs; 2015 Jun 13; 7(4):743-51. PubMed ID: 25970007
    [Abstract] [Full Text] [Related]

  • 3. Simultaneous Targeting of FcγRs and FcαRI Enhances Tumor Cell Killing.
    Brandsma AM, Ten Broeke T, Nederend M, Meulenbroek LA, van Tetering G, Meyer S, Jansen JH, Beltrán Buitrago MA, Nagelkerke SQ, Németh I, Ubink R, Rouwendal G, Lohse S, Valerius T, Leusen JH, Boross P.
    Cancer Immunol Res; 2015 Dec 13; 3(12):1316-24. PubMed ID: 26407589
    [Abstract] [Full Text] [Related]

  • 4. Potent Fc Receptor Signaling by IgA Leads to Superior Killing of Cancer Cells by Neutrophils Compared to IgG.
    Brandsma AM, Bondza S, Evers M, Koutstaal R, Nederend M, Jansen JHM, Rösner T, Valerius T, Leusen JHW, Ten Broeke T.
    Front Immunol; 2019 Dec 13; 10():704. PubMed ID: 31031746
    [Abstract] [Full Text] [Related]

  • 5. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors.
    Stavenhagen JB, Gorlatov S, Tuaillon N, Rankin CT, Li H, Burke S, Huang L, Vijh S, Johnson S, Bonvini E, Koenig S.
    Cancer Res; 2007 Sep 15; 67(18):8882-90. PubMed ID: 17875730
    [Abstract] [Full Text] [Related]

  • 6. IgA EGFR antibodies mediate tumour killing in vivo.
    Boross P, Lohse S, Nederend M, Jansen JH, van Tetering G, Dechant M, Peipp M, Royle L, Liew LP, Boon L, van Rooijen N, Bleeker WK, Parren PW, van de Winkel JG, Valerius T, Leusen JH.
    EMBO Mol Med; 2013 Aug 15; 5(8):1213-26. PubMed ID: 23918228
    [Abstract] [Full Text] [Related]

  • 7. An Engineered Human Fc variant With Exquisite Selectivity for FcγRIIIaV158 Reveals That Ligation of FcγRIIIa Mediates Potent Antibody Dependent Cellular Phagocytosis With GM-CSF-Differentiated Macrophages.
    Kang TH, Lee CH, Delidakis G, Jung J, Richard-Le Goff O, Lee J, Kim JE, Charab W, Bruhns P, Georgiou G.
    Front Immunol; 2019 Aug 15; 10():562. PubMed ID: 30984171
    [Abstract] [Full Text] [Related]

  • 8. iPSC-derived NK cells expressing high-affinity IgG Fc receptor fusion CD64/16A to mediate flexible, multi-tumor antigen targeting for lymphoma.
    Dixon KJ, Snyder KM, Khaw M, Hullsiek R, Davis ZB, Matson AW, Shirinbak S, Hancock B, Bjordahl R, Hosking M, Miller JS, Valamehr B, Wu J, Walcheck B.
    Front Immunol; 2024 Aug 15; 15():1407567. PubMed ID: 39100677
    [Abstract] [Full Text] [Related]

  • 9. Myeloid cells as effector cells for monoclonal antibody therapy of cancer.
    Braster R, O'Toole T, van Egmond M.
    Methods; 2014 Jan 01; 65(1):28-37. PubMed ID: 23811299
    [Abstract] [Full Text] [Related]

  • 10. Expression of a Recombinant High Affinity IgG Fc Receptor by Engineered NK Cells as a Docking Platform for Therapeutic mAbs to Target Cancer Cells.
    Snyder KM, Hullsiek R, Mishra HK, Mendez DC, Li Y, Rogich A, Kaufman DS, Wu J, Walcheck B.
    Front Immunol; 2018 Jan 01; 9():2873. PubMed ID: 30574146
    [Abstract] [Full Text] [Related]

  • 11. The relevance of tumor target expression levels on IgA-mediated cytotoxicity in cancer immunotherapy.
    Chan C, Cabanes NC, Jansen JHM, Guillaume J, Nederend M, Passchier EM, Gómez-Mellado VE, Peipp M, Boes M, van Tetering G, Leusen JHW.
    Cancer Immunol Immunother; 2024 Oct 03; 73(12):238. PubMed ID: 39358557
    [Abstract] [Full Text] [Related]

  • 12. Antitumor immune effector mechanisms recruited by phage display-derived fully human IgG1 and IgA1 monoclonal antibodies.
    Huls G, Heijnen IA, Cuomo E, van der Linden J, Boel E, van de Winkel JG, Logtenberg T.
    Cancer Res; 1999 Nov 15; 59(22):5778-84. PubMed ID: 10582699
    [Abstract] [Full Text] [Related]

  • 13. Triggering Fc alpha-receptor I (CD89) recruits neutrophils as effector cells for CD20-directed antibody therapy.
    Stockmeyer B, Dechant M, van Egmond M, Tutt AL, Sundarapandiyan K, Graziano RF, Repp R, Kalden JR, Gramatzki M, Glennie MJ, van de Winkel JG, Valerius T.
    J Immunol; 2000 Nov 15; 165(10):5954-61. PubMed ID: 11067958
    [Abstract] [Full Text] [Related]

  • 14. Antibody-dependent cell-mediated cytotoxicity effector-enhanced EphA2 agonist monoclonal antibody demonstrates potent activity against human tumors.
    Bruckheimer EM, Fazenbaker CA, Gallagher S, Mulgrew K, Fuhrmann S, Coffman KT, Walsh W, Ready S, Cook K, Damschroder M, Kinch M, Kiener PA, Woods R, Gao C, Dall'Acqua W, Wu H, Coats S.
    Neoplasia; 2009 Jun 15; 11(6):509-17, 2 p following 517. PubMed ID: 19484140
    [Abstract] [Full Text] [Related]

  • 15. Effects of interleukin-18 on natural killer cells: costimulation of activation through Fc receptors for immunoglobulin.
    Srivastava S, Pelloso D, Feng H, Voiles L, Lewis D, Haskova Z, Whitacre M, Trulli S, Chen YJ, Toso J, Jonak ZL, Chang HC, Robertson MJ.
    Cancer Immunol Immunother; 2013 Jun 15; 62(6):1073-82. PubMed ID: 23604103
    [Abstract] [Full Text] [Related]

  • 16. Gene-modified NK-92MI cells expressing a chimeric CD16-BB-ζ or CD64-BB-ζ receptor exhibit enhanced cancer-killing ability in combination with therapeutic antibody.
    Chen Y, You F, Jiang L, Li J, Zhu X, Bao Y, Sun X, Tang X, Meng H, An G, Zhang B, Yang L.
    Oncotarget; 2017 Jun 06; 8(23):37128-37139. PubMed ID: 28415754
    [Abstract] [Full Text] [Related]

  • 17. Dual functional monoclonal antibody PF-04605412 targets integrin alpha5beta1 and elicits potent antibody-dependent cellular cytotoxicity.
    Li G, Zhang L, Chen E, Wang J, Jiang X, Chen JH, Wickman G, Amundson K, Bergqvist S, Zobel J, Buckman D, Baxi SM, Bender SL, Casperson GF, Hu-Lowe DD.
    Cancer Res; 2010 Dec 15; 70(24):10243-54. PubMed ID: 21159645
    [Abstract] [Full Text] [Related]

  • 18. Augmented antibody-based anticancer therapeutics boost neutrophil cytotoxicity.
    Heemskerk N, Gruijs M, Temming AR, Heineke MH, Gout DY, Hellingman T, Tuk CW, Winter PJ, Lissenberg-Thunnissen S, Bentlage AE, de Donatis M, Bögels M, Rösner T, Valerius T, Bakema JE, Vidarsson G, van Egmond M.
    J Clin Invest; 2021 Mar 15; 131(6):. PubMed ID: 33561014
    [Abstract] [Full Text] [Related]

  • 19. FcalphaRI (CD89) as a novel trigger molecule for bispecific antibody therapy.
    Valerius T, Stockmeyer B, van Spriel AB, Graziano RF, van den Herik-Oudijk IE, Repp R, Deo YM, Lund J, Kalden JR, Gramatzki M, van de Winkel JG.
    Blood; 1997 Dec 01; 90(11):4485-92. PubMed ID: 9373259
    [Abstract] [Full Text] [Related]

  • 20. CD24 targeting bi-specific antibody that simultaneously stimulates NKG2D enhances the efficacy of cancer immunotherapy.
    Han Y, Sun F, Zhang X, Wang T, Jiang J, Cai J, Gao Q, Hezam K, Liu Y, Xie J, Wang M, Zhang J.
    J Cancer Res Clin Oncol; 2019 May 01; 145(5):1179-1190. PubMed ID: 30778749
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.